Search This Blog

Wednesday, September 5, 2018

Emirates plane ‘quarantined’ as passengers report ‘feeling sick’ in NY

ng an Emirates flight from Dubai to New York reported feeling ill on a flight to JFK airport, forcing authorities to quarantine the plane.Emirates flight 203

Emirates flight 203 has been quarantined at JFK (Image: LARRY COBEN)
Emirates flight 203 was met at John F Kennedy airport by New York Port Authority Police and officials from the US Centre for Disease Control and Prevention when it landed.
The New York Mayor’s office confirmed the plane had been quarantined at the aiport after landing shortly after 9am local time.
The plane’s pilot had earlier notified the authorities around 100 of his 500 passengers had started to feel sick with fevers and some were coughing, according to initial reports from New York media outlets.
An Emirates spokeswoman later confirmed 10 passengers fell ill on the flight from Dubai to New York.
Larry Cohen, who identified himself as one of the passengers aboard the plane, uploaded photos on Twitter showing dozens of police and emergency vehicles waiting outside the plane on the tarmac.
Mr Cohen told Reuters via Twitter messaging: “All we have been told is that there are some sick passengers and that we need to remain on board.”
An Emirates spokewoman said: “Emirates can confirm that about 10 passengers on board flight EK203 from Dubai to New York were taken ill,” .
“On arrival at JFK, as a precaution, they were immediately checked by local health authorities and those needing medical attention will be attended to.”
She said all other passengers would be allowed to leave the plane shortly.
Officials from the Port Authority Police Department and the US Centre for Disease Control and Prevention are on scene, the New York’ mayor office confirmed.

BioLife ups stake in SAVSU Tech; shares down 16% on potential equity dilution


Thinly traded micro cap BioLife Solutions (BLFS -15.6%) has increased its stake in SAVSU Technologies to 44% with a $5M investment. SAVSU will use the money to scale up its operations and inventory to support market demand for its evo Dry Vapor Shippers and other temperature-controlled shipping containers for cell and gene therapies.
BioLife has an 18-month option to acquire the remaining 56% of SAVSU that it does not own for the greater of 1M shares of stock or $23M worth of stock. If it exercises the option, then 75% would be issued at closing and 25% upon the achievement of certain revenue milestones.

Sangamo hit on results of phase 1/2 gene editing trial


Sangamo Therapeutics Inc. SGMO, -21.00% shares dropped 13% in Wednesday premarket trade after the company released results for a phase 1/2 trial of its gene editing candidate SB-913, which is intended for the rare metabolic disorder Hunter syndrome. Two patients in the clinical trial had reductions of a key biomarker of the disease at 16 weeks, the company said. That and other reductions seen were “encouraging” but the company will need to withdraw enzyme replacement therapy, which is used to manage the disease’s symptoms, to “understand the clinical relevance of these changes,” Dr. Joseph Muenzer, a professor of pediatrics and genetics at the University of North Carolina School of Medicine in Chapel Hill and principal investigator on the study, said in a statement. The trial, called “Champions,” enrolled two patients in three groups, ranging from low to mid and high doses. The company touted the results of two patients in the group on a mid dose of the therapy; enrollment and dosing of patients on the high dose was just completed, it said. Hunter syndrome, also called MPS II, primarily affects boys and causes progressive cell damage. Sangamo’s gene editing candidate aims to treat Hunter syndrome by adding a new copy of a gene into the DNA of a patient’s liver cells. This process was done in vivo, or in the body, marking the first such experiment in humans, the company said; in other types of gene editing and gene therapies, the process is completed outside of the body. SB-913 was generally well-tolerated, according to Sangamo; though two serious side effects were seen, the investigator decided they were primarily related to the disease and not the treatment. Company shares have surged 13.7% over the last three months to $19.05, compared with a 5.4% rise in the S&P 500 SPX, -0.56% and a 4.7% rise in the Dow Jones Industrial AverageDJIA, -0.15%

ProQR gains after upbeat drug trial results


Shares of ProQR Therapeutics NV PRQR, +57.43% rocketed 66% to a near 3-year high in active morning trade Wednesday, to pace gainers on all the major exchanges, after the company said results from a phase 1/2 trial for the treatment of Leber’s congenital amaurosis, a cause for blindness in children, warranted the progression to a phase 2/3 trial. Volume topped 750,000 shares within the first five minutes after the open, compared with the full-day average of about 87,000 shares. The company said in the trial, QR-110 demonstrated “meaningful improvement” in vision, as early as two months after treatment and was stable by three months. The results met the company’s criteria to stop enrollment in the study and progress to a phase 2/3 trial. The stock was trading at the highest levels seen since November 2015. It has now run up more than 4-fold (up 308%) year to date, while the S&P 500 SPX, -0.42% has gained 8.1%.

Piper says investors need exposure to CGM market, prefers DexCom


The strong growth of the continuous glucose monitoring market seen in Q2 will continue for the next several years as CGM pushes towards standard of care in Type 1 diabetes and shows healthy adoption from insulin using Type 2s, Piper Jaffray analyst JP McKim tells investors in a research note. For mass adoption, pricing will need to come down, but even at $3-$4 per day in developed markets CGM is still an $80B worldwide addressable market, the analyst says. He thinks investors “need to have exposure” to the CGM market, and DexCom (DXCM) remains his favorite way to play the space. McKim keeps an Overweight rating on the shares with a $150 price target. He points out that Abbott (ABT), Dexcom and even Medtronic (MDT) posted CGM numbers in Q2 that were much better than expected.

Celyad doses first colorectal cancer patient with CYAD-01


Celyad announced the successful injection of the first patient under the amended protocol of the THINK trial, which assesses treatment with CYAD-01 after a non-myeloablative preconditioning chemotherapy regimen of cyclophosphamide and fludarabine in refractory metastatic colorectal cancer patients.

PerkinElmer upgraded to Equal Weight from Underweight at Barclays


PerkinElmer upgraded to Equal Weight from Underweight at Barclays. Barclays analyst Jack Meehan upgraded to Equal Weight and raised his price target for the shares to $90 from $79.